Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack

Executive Summary

In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.

Advertisement

Related Content

Enthusiasm Builds For Biogen’s BAN2401 In Alzheimer's, But SMA Gene Therapy Hits A Snag
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Eisai Refocuses AiM As It Builds US Immuno-Dementia Research
Eisai Opts In On Biogen's High-Profile Aducanumab

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel